Make your selection

List of Dihydroartemisinin and group ENT Disorder intersectionsRows: 7■ Human ■ Animal ■ Risk ■ Review

SubstanceConditionSeqSrc
PMID
Dtl
Title
Dihydroartemisinin Esophageal Cancer
4
PM
38111311📋Dihydroartemisinin enhances the anti-tumour effect of photodynamic therapy by targeting PKM2-mediated glycolysis in oesophageal cancer cell
Dihydroartemisinin Esophageal Cancer
3
PM
36506308📋Network pharmacology- and molecular docking-based approaches to unveil the pharmacological mechanisms of dihydroartemisinin against esophageal carcinoma
Dihydroartemisinin Esophageal Cancer
1
PM
34744749📋Human Telomerase Reverse Transcriptase as a Therapeutic Target of Dihydroartemisinin for Esophageal Squamous Cancer
Dihydroartemisinin Esophageal Cancer
2
PM
34655567📋Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma
Dihydroartemisinin Head and Neck Cancer
2
PM
38515687📋Regulation of Dihydroartemisinin on the pathological progression of laryngeal carcinoma through the periostin/YAP/IL-6 pathway
Dihydroartemisinin Head and Neck Cancer
1
PM
34755560📋Dihydroartemisinin inhibits IL-6-induced epithelial-mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway
Dihydroartemisinin Oral Cancer
1
PM
34847839📋Dihydroartemisinin represses oral squamous cell carcinoma progression through downregulating mitochondrial calcium uniporter